secwatch / observer
8-K filed March 28, 2022, 7:59 PM ET ticker PETS CIK 0001040130
leadership confidence high sentiment neutral materiality 0.35

PetMed Express appoints Diana Garvis Purcel to board; director Ronald Korn to retire at July 2022 meeting

PETMED EXPRESS INC

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Diana Garvis Purcel

Director
PETS · PETMED EXPRESS INC
Effective
2022-04-04
Filed
March 28, 2022, 7:59 PM ET
the Board of Directors (“Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Diana Garvis Purcel as a director on our Board
Departed

Ronald J. Korn

Director
PETS · PETMED EXPRESS INC
Filed
March 28, 2022, 7:59 PM ET
Ronald J. Korn notified the Board that he intends to retire as a director of the Company at the end of his current term and does not wish to seek reelection at our 2022 Annual Meeting of Stockholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Diana Garvis Purcel was appointed as Director at PETMED EXPRESS INC.

Action
appointed
Role
Director
Exact text from the filing
the Board of Directors (“Board”) of PetMed Express, Inc. (the “Company”) approved the appointment of Diana Garvis Purcel as a director on our Board
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.9

Ronald J. Korn departed as Director at PETMED EXPRESS INC.

Action
intends to retire
Role
Director
Exact text from the filing
Ronald J. Korn notified the Board that he intends to retire as a director of the Company at the end of his current term and does not wish to seek reelection at our 2022 Annual Meeting of Stockholders
View on SEC.gov

PETMED EXPRESS INC filing history →

Source: SEC EDGAR
accession 0001437749-22-007323
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.